BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 13, 2004
View Archived Issues
No difference in risks with tamoxifen use between African American and white breast cancer patients
Read More
Significant relief achieved with octreotide in cluster headache patients
Read More
Novel PDE5 inhibitor from Fujisawa
Read More
Aromatase inhibitor reduces seizure rate in male patients with partial epilepsy
Read More
Clinical benefits of liposteroid therapy in West syndrome patients
Read More
Significant pain relief achieved with levetiracetam in trigeminal neuralgia
Read More
Improved glycemic control achieved with insulin glulisine in type 2 diabetes
Read More
Enrollment completed in SAINT I study of Cerovive in stroke patients
Read More
Wyeth responds to U.K. MHRA's action on Efexor
Read More
U.S. launch of DepoDur
Read More
Myriad files IND for phase I study of MPC-6827
Read More
Serono and Micromet sign collaboration and license agreement for MT-201
Read More
FAST phase II/III study completed for Fibrillex
Read More
Recordati seeks German approval of fixed combination product for hypertension
Read More
Intravenous Boniva submitted for FDA approval
Read More
Swiss clearance for phase I study of 1D09C3
Read More
Nabi eyes StaphVAX filings in Europe and U.S.
Read More
Topigen to conduct pilot study of potential asthma treatment ASM-8
Read More
PTC-124 awarded orphan drug status for cystic fibrosis
Read More
Immune Response Corporation expands MS development program
Read More
Final phase II results confirm the efficacy of telavancin in cSSSI
Read More
Enrollment open in phase Ib study of ARQ-501 and Taxotere
Read More
Update on the safety and antiepileptic effects of UCB-34714
Read More
Enrollment under way in pivotal MS study of MBP-8298
Read More
Palatin reports new agents for the treatment of obesity
Read More
Novel opioid receptor antagonists emerge from Pfizer R&D
Read More
Dabur researchers describe anticancer compounds
Read More
Janssen claims antiinflammatory phospholipase C inhibitors in patent
Read More
New beta-lactamase inhibitors designed by Wyeth researchers
Read More
Roche claims CRF receptor antagonists and their use in stress-related disorders, anxiety, etc.
Read More